Dicerna offering
WebDec 25, 2024 · LEXINGTON, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”), in connection with Novo Nordisk’s cash tender offer for Dicerna expired at 11:59 p.m., Eastern Time, on December 24, … WebAt Dicerna, we use RNA interference, or RNAi, to create medicines that silence or turn off the genes that cause or contribute to disease. Using our GalXC™ and GalXC-Plus™ technologies, we aim to develop safe, …
Dicerna offering
Did you know?
WebAfter finding success with one RNAi candidate for a rare metabolic disorder that impacts the kidneys called primary hyperoxaluria 1, Dicerna Pharmaceuticals was hopeful that a second RNAi candidate WebDicerna. Pharmaceuticals · Massachusetts, United States · 302 Employees . Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and …
WebDec 14, 2024 · CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals (NASDAQ:DRNA) (“Dicerna” or the “Company”), a leading developer of investigational … http://dicerna.com/wp-content/uploads/2024/05/Dicerna-Announces-Proposed-Follow-On-Public-Offering-of-Common-Stock-1.pdf
WebNov 23, 2024 · Novo Nordisk recently offered to buy Dicerna Pharmaceuticals investors an 80% premium for their shares. With a larger pipeline of experimental RNAi drugs in development, Arrowhead Pharmaceuticals...
Web6,150,000 shares of its common stock. In connection with this offering, Dicerna expects to grant the underwriters a 30-day option to purchase up to an additional 922,500 shares of its common stock on the same terms and conditions. The offering is subject to market and other conditions, and there can
WebDicerna has continued to innovate and is exploring new applications of its RNAi technology with GalXC-Plus, extending our expertise in RNAi silencing to address new tissues and organs outside the liver, while retaining key … canateq holdingsWebDec 14, 2024 · Dicerna Pharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery and development of innovative, subcutaneously delivered RNAi-based therapeutics for diseases involving the liver, including rare diseases, chronic liver diseases, cardiovascular diseases, and viral infectious diseases. can a tens unit tone muscleWebJan 31, 2014 · Dicerna priced its initial public offering at $15 a share lateWednesday night, a 25 percent premium over the $11 to $13 range it specified last week. The company sold 6 million shares, raising $90 million and nearly doubling its cash on hand to finance development of drugs to treat cancers and liver diseases based on its gene-silencing ... can a tens unit strengthen musclesWebDec 28, 2024 · Following the expiration of Novo Nordisk’s cash tender offer for Dicerna, Novo Nordisk has today acquired all outstanding shares of common stock of Dicerna at a price of USD 38.25 per share in cash, without interest … can a tens unit help with sciaticaWebNov 18, 2024 · The acquisition supports Novo Nordisk’s strategy of developing and applying a broad range of technology platforms across all Novo Nordisk therapeutic areas. Under the terms of the deal, Novo Nordisk, through a subsidiary, will initiate a tender offer to acquire all outstanding shares of Dicerna common stock at a price of $38.25 per share in cash. fishhook line crossword clueWebNov 2, 2024 · The research collaboration and license agreement could generate up to $201 million for Dicerna. Dicerna’s GalXC platform is designed to work by using RNAi to inhibit the expression of disease ... can a ten year old watch narutohttp://dicerna.com/wp-content/uploads/2024/05/Dicerna-Announces-Proposed-Follow-On-Public-Offering-of-Common-Stock-1.pdf#:~:text=CAMBRIDGE%2C%20Mass.--%28BUSINESS%20WIRE%29--Sep.%205%2C%202424--%20Dicerna%20Pharmaceuticals%2C%20Inc.,the%20actual%20size%20or%20terms%20of%20the%20offering. fishhook lock